NIS

Saudi Arabia Construction Industry Report 2024: Market to Expand by 4.6% in Real Terms this Year, Supported by Public and Private Investments - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 1, 2024
Energy, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Utilities, Construction, Shareek, Saudi Ports Authority, Risk, Housing, Commercial, Climate, Sport, City, Tourism, Yoy, FDI, Sector, Growth, Transport, NEOM, Assessment, SAMA, Central bank, Ministry of Investment, Government, Saudi Vision 2030

The "Saudi Arabia Construction Market Size, Trends, and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2024-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Saudi Arabia Construction Market Size, Trends, and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2024-2028" report has been added to ResearchAndMarkets.com's offering.
  • Construction industry in Saudi Arabia to expand by 4.6% in real terms in 2024, supported by public and private investment in the development of transportation, energy, tourism and housing projects.
  • As of early March 2024, the Kingdom has SAR121.9 billion (32.5 billion) transport infrastructure projects in the bidding stage.
  • Historical (2019-2023) and forecast (2024-2028) valuations of the construction industry in Saudi Arabia, featuring details of key growth drivers.

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

Retrieved on: 
Wednesday, May 1, 2024
Cannabis, Alternative Medicine, Natural Resources, Health, Pharmaceutical, FDA, IDF, Adjustment, GMP, Government, Growth

(NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023.

Key Points: 
  • (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023.
  • Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results.
  • Both Q3&Q4 2023 represents the fourteenth & fifteenth consecutive quarters of profitability for InterCure5, with both Q3&Q4 2023 showing positive Adjusted EBITDA and profit from operations6.
  • Alexander Rabinovitch, CEO of InterCure Noted: "Despite extraordinary external challenges this year, InterCure showed solid performance, achieving our fifteenth straight quarter of profitability.

ManTech Names Barbara Haines-Parmele as Executive Vice President and General Manager of Intelligence Sector

Retrieved on: 
Monday, April 8, 2024
IC, Federation, AI, Mantech, Intelligence community, INSA, Intelligence, Organization development, Pennsylvania State University, Management

HERNDON, Va., April 08, 2024 (GLOBE NEWSWIRE) -- ManTech, a leading provider of AI and mission-focused technology solutions, today announced that it has promoted Barbara Haines-Parmele to Executive Vice President and General Manager of the company’s Intelligence Sector.

Key Points: 
  • HERNDON, Va., April 08, 2024 (GLOBE NEWSWIRE) -- ManTech, a leading provider of AI and mission-focused technology solutions, today announced that it has promoted Barbara Haines-Parmele to Executive Vice President and General Manager of the company’s Intelligence Sector.
  • Reporting to CEO and President Matt Tait, Haines-Parmele will lead strategic and operational initiatives to address the Intelligence Community’s (IC) most critical missions.
  • “As a ManTech leader, Barbara excels in client satisfaction, workforce management and financial performance that drive business growth.”
    Previously, Haines-Parmele served as Vice President of the National Intelligence Solutions (NIS) Division – part of ManTech’s Intelligence Sector.
  • She joined ManTech as a program manager in 2006 and since 2018 has served as Vice President leading programs supporting key Intelligence Community clients.

EU's reimagined NIS 2 cybersecurity vision puts businesses on high alert

Retrieved on: 
Friday, April 5, 2024
NordLayer, Health, Union, Culture, Organization, Waste management, Face, Risk management, Exercise, Network, Intelligence, Information, Cyber-security regulation, Lung compliance, Medical device

The NIS 2 aims to establish a high standard level of cybersecurity and resilience throughout the Union.

Key Points: 
  • The NIS 2 aims to establish a high standard level of cybersecurity and resilience throughout the Union.
  • "The NIS 2 represents a significant step forward in unifying and elevating cybersecurity standards across our critical economic sectors and digital infrastructure."
  • As an advocate of effective cybersecurity solutions, we are committed to enabling organizations to navigate the NIS 2 compliance journey.
  • The Network and Information Security 2 Directive (NIS 2) is an update and expansion of the original 2016 NIS Directive.

SaverOne Reports Full Year 2023 Results with 128% Year-over-Year Revenue Growth

Retrieved on: 
Monday, March 25, 2024
ADAS, Transport, Bank statement, OEM, Volvo, European, Marketing, Research, Volvo Buses, Strauss Group, Annual report, Cemex, Hospital, Engineering, Aircraft, Growth, Operating cost, Bank, Net, Patent, IASB, Airline

In September 2023, SaverOne launched its first European pilot with Cemex in Spain, covering ten trucks in two regions.

Key Points: 
  • In September 2023, SaverOne launched its first European pilot with Cemex in Spain, covering ten trucks in two regions.
  • In October 2023, SaverOne announced the win of six new customers covering 90 vehicles in the private bus fleet industry in Israel.
  • In October 2023, SaverOne signed a distribution agreement with GVZ Company, based in Milan, specializing in the distribution of automotive components and solutions in European markets.
  • In February 2024, SaverOne announced that Egged Tours would install 300 SaverOne Systems on all its buses.

Azrieli Group Reports Q4/2023 and Y2023 Results

Retrieved on: 
Thursday, March 21, 2024
Growth, Azrieli Group, Property, Azrieli, Iron, Sale, Question and Answer, CBD, Bank Leumi, NOI, Bank statement, Investment, Lehavim, FFO

NIS 1 billion

Key Points: 
  • NIS 1 billion
    Danna Azrieli, Chairwoman of Azrieli Group: “2023 was a challenging year for Israeli society, even before the outbreak of the Iron Swords War.
  • Eyal Henkin, CEO of Azrieli Group: “We are ending a year full of activity and continued growth, with the relief given to the tenants of our malls due to the Iron Swords War having had a relatively moderate impact on the Q4 results.
  • NOI in Y2023 was up around 8% and totaled some NIS 2,113 million, compared with some NIS 1,953 million year-over-year.
  • The accounting effects of the transaction were recorded in Q4, and the operating results of Compass are not included starting from Q3/2023 results.

Formula Systems Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Hamas, Tax, Tel Aviv Stock Exchange, Iron, TSG, Matrix, Formula, American depositary receipt, Investment, Formula Systems

Financial Highlights for the Fourth Quarter Ended December 31, 2023

Key Points: 
  • Financial Highlights for the Fourth Quarter Ended December 31, 2023
    Consolidated revenues for the fourth quarter ended December 31, 2023 amounted to $640.3 million, compared to $657.1 million in the same period last year.
  • Consolidated operating income for the fourth quarter ended December 31, 2023 amounted to $60.3 million compared to $60.2 million in the same period last year.
  • The absence of such employees resulted in lower profitability in the fourth quarter in certain areas of our operations.
  • Actual ratio of net financial indebtedness to net capitalization, as of December 31, 2023, was 1%.

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

Retrieved on: 
Monday, April 1, 2024
Other Health, Banking, General Health, Cannabis, Professional Services, Pharmaceutical, Medical Devices, Natural Resources, Insurance, Alternative Medicine, Finance, Health, Annual report, Growth, Partnership, Patient, GMP, TYSON, Government, 20F, Drug

(NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 2023.

Key Points: 
  • (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 2023.
  • Annual revenue for 2023 is estimated at NIS 351 million, and revenue for the H2 2023 is estimated at NIS 140 million.
  • EBITDA for 2023 is estimated at over NIS 50 Million, and H2 2023’s EBITDA is estimated to reach over NIS 20 million and over 14% of revenues.
  • Both Q3&Q4 2023 represents the fourteenth & fifteenth consecutive quarter of profitability for InterCure, with both Q3&Q4 showing a positive EBITDA and profit from operations.

Phoenix Holdings Publishes Financial Statements for Q4 and 2023

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Business, Insurance, Finance, Asset Management, Consulting, Banking, Friends, The Phoenix Companies, Growth, Memory, Share repurchase, Corporation, Policy, TLV, Acquisition, Tel Aviv Stock Exchange, Life, Credit, Solvency, Asset management, Report, SME, Analyst, Safety, Barzilai Medical Center, P&C, Holding, Collection, Pain, Rehabilitation, Mobile phone

Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.

Key Points: 
  • Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.
  • Phoenix is financially resilient with high levels of liquidity and a high Solvency II ratio for Phoenix Insurance, which reached 209% with transitional measures as of September 30, 2023.
  • Comprehensive income before tax in 2023 amounted to NIS 241 million, compared to NIS 235 million in 2022.
  • Comprehensive income before tax in 2023 amounted to NIS 307 million, compared to NIS 300 million in 2022.

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

Retrieved on: 
Wednesday, April 3, 2024
Momentum, Patient, History, Sale, IP, Endometriosis, Depreciation, USD, Marketing, Regulation, Research, Classification, Webcast, Freezing, Woman, Breast cancer, ICE3, Food, Case Western Reserve University, Neoplasm, Cancer, LN2, GAAP, FDA, Annual general meeting, Health, Conference call, Growth, The Twelve Months, Recurrence, Society, Patent, Physician, Kidney cancer

CAESAREA, Israel, April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported sales as of and for the twelve months ended December 31, 2023 increased 26% compared to the twelve months ended December 31, 2022, as the Company continues to transition from a research and development and clinical phase company to a commercial phase company.

Key Points: 
  • Our U.S. commercial team is ready to launch marketing and distribution of ProSense® for breast cancer as we await the U.S. Food and Drug Administration's ("FDA") decision.
  • Should the FDA grant clearance, we believe this decision would further boost commercial demand in global markets where ProSense® already has approval for breast cancer."
  • "As we increased our commercial activities through medical conferences and added more distributors, we had a corresponding growth in 2023 revenues, system, and probe sales.
  • The FDA requested this data as part of IceCure's De Novo Classification Request for Marketing Authorization of ProSense® for the treatment of early-stage low-risk breast cancer.